Peptide
Lutetium-177 Dotatate (Lutathera)
Lutetium-177 dotatate is a radiolabeled somatostatin analog for peptide receptor radionuclide therapy (PRRT). FDA-approved 2018 for SSTR-positive GEP-NETs. NETTER-1 Phase 3: 65.2% PFS at 20 months vs 10.8% control. 79% reduction in disease progression/death risk. Median OS 48 months vs 36.3 months. First radiopharmaceutical for NETs.
- Updated
- How we grade
- 40 studies cited
Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.
- Best evidence
- Grade A
- Conditions studied
- 1
- Outcomes
- 10
- Graded outcomes
- 4213
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
General
Key findings
- Progression-Free SurvivalImproves (the measure goes up)
- Overall SurvivalImproves (the measure goes up)
- Objective Response RateImproves (the measure goes up)
Safety notes in the studies
- 79% reduction in progression/death risk.
Studies cited
40 studies from PubMed
- Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial
- Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [177Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the Phase III NETTER-1 Trial
- Evaluation of the Real-Life Efficacy and Safety of the Treatment with Lutetium-177 Dotatate for Metastatic Neuroendocrine Tumors.
- Efficacy and Safety of Radioligand Therapy with Actinium-225 DOTATATE in Patients with Advanced, Metastatic or Inoperable Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis.
- Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms.
- 177Lu-DOTATATE in Peptide Receptor Radionuclide Therapy: A Decade of Experience and Evolution
- Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.
- Comparison of the tolerability of (161)Tb- and (177)Lu-labeled somatostatin analogues in the preclinical setting.
- Time toxicity of lutetium 177 in gastroenteropancreatic neuroendocrine tumours.
- 177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review.
- Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment.
- Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals.
- Safety and Efficacy of 177 Lu-DOTATATE in Neuroendocrine Tumor Patients With Extensive Bone Disease.
- Survival and Response Outcomes for Gastrointestinal Neuroendocrine Tumor (GEP-NETs) Patients Treated with Lutetium-177-DOTATATE in a Brazilian Reference Center: A Six-Year Follow-Up Experience.
- A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements.
- An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 ((177)Lu)-DOTATATE.
- Lutetium-177 DOTATATE: A Practical Review.
- Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review.
- 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
- NETTER-2 trial protocol: a prospective, international, open-label, randomized phase 3 study of 177Lu-DOTATATE compared with octreotide LAR in somatostatin receptor-positive, grade 2-3, midgut neuroendocrine tumors
- Initial experience and lessons learned with implementing Lutetium-177-dotatate radiopharmaceutical therapy in a radiation oncology-based program.
- A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy.
- Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE.
- Cost-effectiveness of lutetium ((177)Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden.
- Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial).
- Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.
- Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
- 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
- Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review.
- Therapy With (177)Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors.
- Protection of Kidney Function with Human Antioxidation Protein α(1)-Microglobulin in a Mouse (177)Lu-DOTATATE Radiation Therapy Model.
- Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial
- Gastroenteropancreatic Neuroendocrine Tumors.
- The effect of kidney volume estimation on dosimetry in lutetium-177 DOTATATE therapy.
- Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.
- Medical Therapy of Gastrointestinal Neuroendocrine Tumors.
- Early efficacy of and toxicity from lutetium-177-DOTATATE treatment in patients with progressive metastatic NET.
- 177Lu-DOTATATE for the Treatment of Midgut Neuroendocrine Tumors: Long-term Results in 229 Patients